Form 4 for ANIX Anixa Biosciences Inc
Accepted 2023-05-01 00:00:00 ET · period of report 2023-04-28 · accession 0001493152-23-014890 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-01 | 2023-04-28 | ANIX | Catelani Michael | Pres, COO, CFO | A - Grant | $3.47 | +865 | 21.2K | +4% | +$3,002 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-28 | A | A | 865 | $3.47 | 21,155 | D | — | — | (F2) In accordance with the Plan, the shares were purchased based on 85% of the closing price of Anixa Biosciences, Inc. common stock on April 28, 2023. |